ImmunityBio has resubmitted its supplemental biologics license application to the U.S. Food and Drug Administration for ANKTIVA (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guerin for BCG-unresponsive non-muscle invasive bladder cancer with papillary tumors, after the agency requested updated long-term efficacy data in March 2026. The resubmission follows a regulatory exchange that began in January 2026 and did not require new clinical trials, with the agency having already reviewed additional data submitted by the U.S.-based biotech in February before requesting the further update. The FDA has acknowledged receipt of the resubmitted filing.
Why the FDA’s request for updated data signals continued regulatory uncertainty for ANKTIVA papillary expansion
The sequence of this regulatory exchange is worth examining closely. ImmunityBio submitted additional information in February 2026 following FDA requests made in January. The agency reviewed that material and then, in March, returned with a further ask for updated efficacy data before the company could resubmit. For investors and observers tracking this program, the back-and-forth underscores that the papillary indication carries a meaningfully different evidentiary burden than the carcinoma-in-situ indication for which ANKTIVA received FDA approval in 2024.
That 2024 approval covered BCG-unresponsive NMIBC with carcinoma in situ, a disease subtype characterised by diffuse flat lesions and higher near-term progression risk. The papillary extension involves a biologically and clinically distinct patient population, one where treatment decisions hinge heavily on long-term disease-free survival and bladder preservation rather than complete response rates alone. The FDA’s insistence on updated follow-up data suggests the agency wanted maturity in the outcome curves before accepting the dossier for full review, rather than relying on the published 2025 data in The Journal of Urology, which itself represented the longest reported follow-up in this population.
What the QUILT 3.032 trial data actually shows and where the evidentiary gaps remain for regulators
The clinical case rests on results from Cohort B of the QUILT 3.032 Phase 2/3 trial, which enrolled 80 patients with high-grade papillary-only NMIBC. The primary endpoint, a 12-month disease-free survival rate of 58.2%, sits within a confidence interval of 46.6% to 68.2%, a range regulators will scrutinise for statistical robustness given the modest sample size. Disease-specific survival reached 96.0% at 36 months, and cystectomy-free survival held at 81.8% at 36 months, suggesting that more than four in five patients avoided radical surgery through three years of follow-up.
Those are clinically meaningful numbers, particularly given that bladder preservation is a central quality-of-life concern in this patient population. However, the absence of a randomised comparator arm complicates direct interpretation. Single-arm Phase 2/3 trials in BCG-unresponsive NMIBC have historically faced regulatory friction, even when outcomes appear strong, because the counterfactual of what would have occurred with surveillance alone or alternative salvage therapy remains unclear. Regulatory watchers suggest the FDA may be seeking updated data partly to assess durability of response at longer time points before granting approval, especially given the relatively small cohort.
How the approved CIS indication and the pending papillary sBLA relate to each other commercially and scientifically
The strategic logic behind the papillary expansion is straightforward. Approximately 60,000 new NMIBC diagnoses occur in the United States each year, and around 70% of these cases involve papillary disease. The existing ANKTIVA approval for CIS, while significant, addresses a smaller fraction of the NMIBC population. A successful papillary label extension would substantially broaden the addressable patient base and, by extension, the commercial opportunity for the drug within the intravesical therapy market.
The two indications share a mechanistic rationale. ANKTIVA functions as an IL-15 receptor agonist, activating natural killer cells and CD8-positive cytotoxic T cells while generating memory T cell populations that may provide durable surveillance against residual tumor clones. Industry observers note that this mechanism, which the National Cancer Institute identified in 2007 as a high-priority immunotherapy target, is now supported by both an active commercial approval and a growing body of long-term follow-up data. Whether that mechanistic coherence is sufficient to satisfy FDA review standards for the papillary population remains the open question.
What the Saudi SFDA approval of ANKTIVA in lung cancer reveals about ImmunityBio’s regulatory diversification strategy
Running parallel to the bladder cancer regulatory activity, ImmunityBio recently received approval from Saudi Arabia’s Food and Drug Authority for ANKTIVA in combination with checkpoint inhibitors for second-line and later metastatic non-small cell lung cancer. The SFDA approval is notable because it targets a disease setting in which multiple randomised trials of investigational agents have failed to improve outcomes over docetaxel chemotherapy, the current standard of care for patients who have progressed after initial checkpoint inhibitor treatment.
The QUILT 3.055 study data cited in support of the SFDA approval reportedly demonstrated approximately double the median overall survival seen historically with docetaxel. Clinicians tracking the lung cancer field will note that the PRAGMATICA-LUNG trial, which tested pembrolizumab plus ramucirumab versus docetaxel in a similar setting, reported a median overall survival of roughly nine months with docetaxel and failed to show improvement over that benchmark. If ImmunityBio’s data holds under further scrutiny, the clinical case for ANKTIVA in second-line NSCLC could represent a genuine step forward in a space that has accumulated a series of late-stage failures.
Whether the SFDA approval translates into a U.S. regulatory submission for the NSCLC indication is unclear. The company has stated it intends to continue discussions with the FDA and other global regulatory authorities, but no formal U.S. filing timeline has been disclosed. Industry observers will be watching for the full clinical dataset from the QUILT 3.055 trial to assess whether the survival benefit is robust enough to support a registrational program in the United States, where the FDA’s evidence standards for second-line NSCLC are well established and competition from emerging agents remains intense.
What risks and unresolved questions remain for ANKTIVA before papillary approval and broader commercial uptake
The most immediate risk for the papillary program is another request for additional information from the FDA, which would extend the review timeline further and potentially compress the commercial window before generic or biosimilar competition emerges in adjacent treatment categories. The company has navigated two rounds of FDA data requests in the span of roughly two months, and while the resubmission has been acknowledged, there is no guarantee the current filing will proceed to a PDUFA date without further back-and-forth.
Beyond the regulatory pathway, commercial execution in the NMIBC space presents its own challenges. Intravesical delivery requires trained urologists and appropriate clinical infrastructure, and BCG supply constraints have historically disrupted treatment access for patients with NMIBC. Adoption of ANKTIVA plus BCG in the CIS setting will inform payer and prescriber readiness for the papillary indication, but the real-world uptake data is still early.
Reimbursement dynamics also merit scrutiny. Payers evaluating a bladder-preserving immunotherapy regimen will weigh the upfront treatment cost against the long-term cost avoidance of deferring or avoiding radical cystectomy, a procedure that carries substantial morbidity and long-term care costs. The 81.8% cystectomy-free survival at 36 months is the data point most likely to feature in health economic analyses, but those analyses have not yet been published or formally submitted to payers.
For clinicians and regulators watching the bladder cancer space, the ANKTIVA papillary resubmission represents one of the more substantive near-term regulatory decisions in a field that has seen limited new approvals. Whether the updated long-term follow-up data is sufficient to clear the FDA’s evidentiary bar will shape both the clinical management of high-grade papillary NMIBC and the commercial trajectory of ImmunityBio’s intravesical franchise.
ImmunityBio resubmits FDA application for ANKTIVA in bladder cancer after agency requests updated efficacy data added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →